Skip to main content

Dako, Amgen to Collaborate on Personalized Cancer Dx

NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with Amgen to develop a diagnostic test for a drug candidate for treating a rare and deadly form of cancer.

The company did not specify the type of cancer Amgen will target in this collaboration.

"Our agreement with Amgen is one of several partnerships that Dako has entered with pharma companies to enable the development of diagnostic tests to predict which patients are most likely to respond to specific treatments," Dako CEO Lars Holmkvist said in a statement.

The company has struck similar agreements over the past two years with AstraZeneca, Bristol-Myers Squibb, and Genentech.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.